U3-1402 sensitizes HER3-expressing tumors to PD-1 blockade by immune activation

Immunotherapy targeting programmed cell death-1 (PD-1) induces durable antitumor efficacy in many types of cancer. However, such clinical benefit is limited because of the insufficient reinvigoration of antitumor immunity with the drug alone; therefore, rational therapeutic combinations are required...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:J Clin Invest
Glavni autori: Haratani, Koji, Yonesaka, Kimio, Takamura, Shiki, Maenishi, Osamu, Kato, Ryoji, Takegawa, Naoki, Kawakami, Hisato, Tanaka, Kaoru, Hayashi, Hidetoshi, Takeda, Masayuki, Maeda, Naoyuki, Kagari, Takashi, Hirotani, Kenji, Tsurutani, Junji, Nishio, Kazuto, Doi, Katsumi, Miyazawa, Masaaki, Nakagawa, Kazuhiko
Format: Artigo
Jezik:Inglês
Izdano: American Society for Clinical Investigation 2019
Teme:
Research Article
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC6934205/
https://ncbi.nlm.nih.gov/pubmed/31661465
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1172/JCI126598
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items